The Supreme Court on Monday declined to consider a patent dispute between biotech drug maker Amgen Inc. and two other companies involving Amgen's blockbuster anemia drug Epogen. Amgen urged the justices to rule on the Federal Circuit's practice of considering the factual record behind its patent claims, stating in its filing that the practice "produces incorrect results and causes litigants and district courts to waste tremendous resources."
May 15, 2007 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
The Supreme Court on Monday declined to consider a patent dispute between biotech drug maker Amgen Inc. and two other companies involving Amgen’s blockbuster anemia drug Epogen.
Despite passing on this case, justices have shown a heightened interest in patent law recently, taking up a half-dozen cases in the past two years and issuing two high-profile decisions in April.
Presented by BigVoodoo
Honoring outstanding legal achievements focused at the national level, largely around Big Law and in-house departments.
Women Leaders in Consulting Awards honors the industry standouts and rising stars who are making a mark within the profession.
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
General Statement of DutiesPerforms legal work involving full litigation of all types of matters both for and against the Town, including al...
Shipman & Goodwin LLP is seeking a attorney to expand our national commercial real estate lending practice. Candidates should have a mi...
Health Law Associate CT Shipman is seeking an associate to join our national longstanding health law practice. Candidates must have t...
